We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

DNX and XL-protein Announce Collaboration

DNX and XL-protein Announce Collaboration

DNX and XL-protein Announce Collaboration

DNX and XL-protein Announce Collaboration

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DNX and XL-protein Announce Collaboration"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DNX Biopharmaceuticals, Inc. and XL-protein GmbH have announced a collaboration for the development and commercialization of novel, long-acting biopharmaceutical products. Under this strategic collaboration, XLp will contribute its half-life extension platform technology (PASylation®) and certain molecules that have completed in vivo efficacy proof-of-concept and preclinical studies, and DNX will add its pipeline of candidate molecules for development and commercialization to address a range of unmet needs in Immunology, Metabolism and Ophthalmology. Financial terms have not been disclosed.

Half-life extension is a critical aspect of developing a successful protein pharmaceutical, as not all efficacious payloads have natural half-lives that are amenable to reasonable dosing intervals or regimens.

The novel PASylation platform is designed to offer improved half-life, pharmacokinetics, pharmacodynamics, bioavailability, solubility and overall enhanced patient compliance and safety. PASylation is a highly tunable technology and offers a paradigm shift in patient care and better compliance in multiple therapeutic areas to improve the quality of life for millions of patients.

"We are pleased to be partnering with XL-protein on the development of new molecules specifically designed to improving the lives of patients, while simultaneously helping to alleviate the clinical burden," said Dr. Rajiv Datar, Chief Executive of DNX. "By combining DNX's 250+ person-years of experience of biologics process development, clinical development and GMP manufacturing expertise with XLp's revolutionary PASylation platform, we hope to 'Make Good Drugs Great,' and to delivering more gain and less pain to patients."

"Working with DNX to create a range of novel long-acting biopharmaceuticals that will provide benefits to patients and to the healthcare services by reducing clinical burden is exciting and satisfying," said Claus Schalper, Managing Director of XL-protein.

Schalper continued, "Our team shares a common passion with DNX to 'Making Good Drugs Even Greater' by contributing our half-life extension / drug delivery technology to support successful product development and commercialization."